Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Tax Provisions (2016 - 2026)

Oramed Pharmaceuticals filings provide 5 years of Tax Provisions readings, the most recent being -$7.9 million for Q4 2025.

  • Quarterly Tax Provisions fell 2010.34% to -$7.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, up 12.25% year-over-year, with the annual reading at $3.6 million for FY2025, 12.25% up from the prior year.
  • Tax Provisions hit -$7.9 million in Q4 2025 for Oramed Pharmaceuticals, down from $11.1 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $11.1 million in Q3 2025 and bottomed at -$7.9 million in Q4 2025.
  • Average Tax Provisions over 3 years is $857000.0, with a median of $500000.0 recorded in 2024.
  • Peak annual rise in Tax Provisions hit 876.35% in 2025, while the deepest fall reached 2010.34% in 2025.
  • Oramed Pharmaceuticals' Tax Provisions stood at $100000.0 in 2022, then surged by 316.0% to $416000.0 in 2024, then crashed by 2010.34% to -$7.9 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Tax Provisions are -$7.9 million (Q4 2025), $11.1 million (Q3 2025), and -$126000.0 (Q2 2025).